Trestle Biotherapeutics
Trestle Biotherapeutics, based in San Diego, develops implantable therapeutic tissues to aid patients with end-stage renal disease, aiming to reduce reliance on dialysis.
Company Overview
Trestle Biotherapeutics, based in San Diego, CA, USA, operates within the Healthcare and Industrial Bio industries. The company is actively working on developing implantable therapeutic tissue for patients with end stage renal disease. The innovative bioengineered kidneys they are creating aim to supplement renal function and potentially eliminate the need for dialysis. Trestle Biotherapeutics is in the early stages of development and is part of the Y Combinator W21 batch. The team consists of 2 members and the company is supported by investors including Y Combinator and Formic Ventures.
Innovations in End Stage Renal Disease Treatment
Trestle Biotherapeutics is focusing on creating implantable therapeutic tissues designed to aid patients with end stage renal disease. Their technology aims to support and enhance renal function, potentially allowing patients to reduce or eliminate dialysis dependency. By bioengineering kidneys, Trestle aims to offer a significant improvement in the management of kidney failure, contributing to better health outcomes for affected individuals.
Y Combinator W21 Batch Participation
Trestle Biotherapeutics was a participant in the Y Combinator W21 batch. As part of this prestigious startup accelerator program, the company has received valuable support and guidance. Their participation in Y Combinator also led to notable recognition, including being highlighted by TechCrunch as one of the top biotech companies during Y Combinator’s W21 Demo Day. This involvement has helped Trestle Biotherapeutics to attract the attention of investors and industry stakeholders.
Achievements and Accolades
Trestle Biotherapeutics has received substantial recognition and support for its innovative work in the healthcare sector. They were awarded a $1 million prize from the KidneyX Innovation Accelerator through the Artificial Kidney Prize program. Additionally, the company joined the Wellcome Leap HOPE program, further highlighting its commitment to advancing healthcare solutions for end stage renal disease.